Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis

BIBF 1000 is a small molecule inhibitor targeting the receptor kinases of platelet-derived growth factor (PDGF), basic fibroblast growth factor and vascular endothelial growth factor, which have known roles in the pathogenesis of pulmonary fibrosis. The anti-fibrotic potential of BIBF 1000 was determined in a rat model of bleomycin-induced lung fibrosis and in an ex vivo fibroblast differentiation assay. Rats exposed to a single intra-tracheal injection of bleomycin were treated with BIBF 1000 starting 10 days after bleomycin administration. To gauge for anti-fibrotic activity, collagen deposition and pro-fibrotic growth factor gene expression was analysed in isolated lungs. Furthermore, the activity of BIBF 1000 was compared with imatinib mesylate (combined PDGF receptor, c-kit and c-abl kinase inhibitor) and SB-431542 (transforming growth factor (TGF)-β receptor I kinase inhibitor) in an ex vivo TGF-β-driven fibroblast to myofibroblast differentiation assay, performed in primary human bronchial fibroblasts. Treatment of rats with BIBF 1000 resulted in the attenuation of fibrosis as assessed by the reduction of collagen deposition and the inhibition of pro-fibrotic gene expression. In the cellular assay both SB-431542 and BIBF 1000 showed dose-dependent inhibition of TGF-β-induced differentiation, whereas imatinib mesylate was inactive. BIBF 1000, or related small molecules with a similar kinase inhibition profile, may represent a novel therapeutic approach for the treatment of idiopathic pulmonary fibrosis.

[1]  A. Schnapp,et al.  Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. , 2006, American journal of respiratory and critical care medicine.

[2]  Antje Prasse,et al.  A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. , 2006, American journal of respiratory and critical care medicine.

[3]  J. Tchinda,et al.  Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. , 2006, Blood.

[4]  S. Huet,et al.  Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. , 2006, Drug news & perspectives.

[5]  S. Ōmura,et al.  EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts , 2006, Respiratory research.

[6]  A. Kurosaki,et al.  High-Resolution Computed Tomography Findings of Lung Cancer Associated With Idiopathic Pulmonary Fibrosis , 2006, Journal of computer assisted tomography.

[7]  V. Duronio,et al.  Proliferation of Pulmonary Interstitial Fibroblasts Is Mediated by Transforming Growth Factor-β1-induced Release of Extracellular Fibroblast Growth Factor-2 and Phosphorylation of p38 MAPK and JNK* , 2005, Journal of Biological Chemistry.

[8]  A. Masamune,et al.  Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. , 2005, World journal of gastroenterology.

[9]  F. Oakley,et al.  The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis , 2005, Apoptosis.

[10]  S. Lepreux,et al.  Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. , 2005, The international journal of biochemistry & cell biology.

[11]  Jesús Prieto,et al.  Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. , 2005, The Journal of investigative dermatology.

[12]  M. Hetzel,et al.  Different Effects of Growth Factors on Proliferation and Matrix Production of Normal and Fibrotic Human Lung Fibroblasts , 2005, Lung.

[13]  S. Sone,et al.  Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. , 2005, American journal of respiratory and critical care medicine.

[14]  W. Kilarski,et al.  An ex vivo model for functional studies of myofibroblasts , 2005, Laboratory Investigation.

[15]  M. Kolb,et al.  Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. , 2005, American journal of respiratory and critical care medicine.

[16]  Fabian Kiessling,et al.  Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis , 2005, The Journal of experimental medicine.

[17]  I. Yamaguchi,et al.  The Peroxisome Proliferator-activated Receptor α Activator Fenofibrate Inhibits Endothelin-1-induced Cardiac Fibroblast Proliferation , 2004, Journal of cardiovascular pharmacology.

[18]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[19]  J. Bonner,et al.  Regulation of PDGF and its receptors in fibrotic diseases. , 2004, Cytokine & growth factor reviews.

[20]  M. Keane.  Angiogenesis and pulmonary fibrosis: feast or famine? , 2004, American journal of respiratory and critical care medicine.

[21]  K. Brown,et al.  Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. , 2004, American journal of respiratory and critical care medicine.

[22]  Alexander Levitzki,et al.  PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. , 2004, Cytokine & growth factor reviews.

[23]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[24]  Hiroyuki Aburatani,et al.  SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. , 2003, Cancer research.

[25]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[26]  S. Dacic,et al.  Histologic classification of idiopathic chronic interstitial pneumonias. , 2003, American journal of respiratory cell and molecular biology.

[27]  R. Heller,et al.  Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. , 2003, The American journal of pathology.

[28]  B. Winston,et al.  Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. , 2002, Chest.

[29]  D. A. Schwartz,et al.  Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. , 2002, American journal of respiratory and critical care medicine.

[30]  B. Olson,et al.  Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .

[31]  Y. Soini,et al.  VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia , 2002, The Journal of pathology.

[32]  L. Wakefield,et al.  TGF-β signaling: positive and negative effects on tumorigenesis , 2002 .

[33]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[34]  P. Jeffery.  Remodeling in asthma and chronic obstructive lung disease. , 2001, American journal of respiratory and critical care medicine.

[35]  R. Djukanović,et al.  The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. , 2001, American journal of respiratory cell and molecular biology.

[36]  N. Goldsack,et al.  Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. , 2001, The American journal of pathology.

[37]  D. Anthony,et al.  Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. , 2001, The Journal of clinical investigation.

[38]  Naftali Kaminski,et al.  TGF-β is a critical mediator of acute lung injury , 2001 .

[39]  M. Selman,et al.  Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. , 2001, American journal of respiratory cell and molecular biology.

[40]  N. Aoike,et al.  Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. , 2001, The Journal of allergy and clinical immunology.

[41]  P. Howarth,et al.  Epithelial-mesenchymal interactions in the pathogenesis of asthma , 2003 .

[42]  M. Haase,et al.  Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis , 1999, Virchows Archiv.

[43]  S. G. Jones,et al.  TGF-βbgr;1 stimulates the release of pre-formed bFGF from renal proximal tubular cells , 1999 .

[44]  S. Holgate,et al.  The bronchial epithelium as a key regulator of airway inflammation and remodelling in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[45]  S. Holgate,et al.  Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: an in vitro co-culture model of airway remodeling in asthma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[46]  J. Lasky,et al.  Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[47]  R. D. du Bois,et al.  Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. , 1997, The American journal of pathology.

[48]  A. Eddy.  Molecular insights into renal interstitial fibrosis. , 1996, Journal of the American Society of Nephrology : JASN.

[49]  I. Sarosi,et al.  Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. , 1996, The American journal of pathology.

[50]  M. Selman,et al.  Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. , 1995, The American journal of physiology.

[51]  T. Colbert,et al.  TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. , 1995, Journal of immunology.

[52]  G. Laurent,et al.  The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. , 1991, Biochimica et biophysica acta.

[53]  R. Ross,et al.  TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. , 1990, Cell.

[54]  P. Howarth,et al.  Myofibroblasts and subepithelial fibrosis in bronchial asthma. , 1990, American journal of respiratory cell and molecular biology.

[55]  S. Holgate,et al.  SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS , 1989, The Lancet.

[56]  S. Dower,et al.  Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. , 1989, Science.

[57]  J. Folkman,et al.  Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Turner-Warwick,et al.  Precapillary Systemic-pulmonary Anastomoses , 1963, Thorax.

[59]  W. Qi,et al.  The renal cortical fibroblast in renal tubulointerstitial fibrosis. , 2006, The international journal of biochemistry & cell biology.

[60]  濱田 直樹.  Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice , 2006 .

[61]  J. Myers,et al.  Idiopathic pulmonary fibrosis in patients younger than 50 years. , 2005, Mayo Clinic proceedings.

[62]  J. Lasky,et al.  Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[63]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[64]  L. Wakefield,et al.  TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. , 2003, The Journal of clinical investigation.

[65]  L. Wakefield,et al.  TGF-beta signaling: positive and negative effects on tumorigenesis. , 2002, Current opinion in genetics & development.

[66]  N. Kaminski,et al.  TGF-beta is a critical mediator of acute lung injury. , 2001, The Journal of clinical investigation.

[67]  T. Horie,et al.  Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. , 2001, American journal of respiratory and critical care medicine.

[68]  T. Horie,et al.  Transforming Growth Factor- β1 Induces Phenotypic Modulation of Human Lung Fibroblasts to Myofibroblast Through a c-Jun-NH2-Terminal Kinase-Dependent Pathway , 2001 .

[69]  A. Phillips,et al.  TGF-beta1 stimulates the release of pre-formed bFGF from renal proximal tubular cells. , 1999, Kidney international.